National Bank of Canada
VRAX icon

National Bank of Canada’s Virax Biolabs VRAX Stock Holding History

National Bank of Canada’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-240
Closed -$2.07K – 3215
2025
Q4 		$2.07K Sell
240
-160
-40% -$2.04K ﹤0.01% 2560
2025
Q3 		$6K Buy
400
+200
+100% +$3.81K ﹤0.01% 2430
2025
Q2 		$3.95K Buy
+200
New +$4.88K ﹤0.01% 2534

Other funds holding VRAX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

National Bank of Canada's VRAX Position: Q1 2026 in Review

National Bank of Canada sold out of Virax Biolabs (VRAX) in Q1 2026, closing a stake of 240 shares — an estimated $2.07K sold.

National Bank of Canada first reported a position in VRAX in Q2 2025 and held it in 3 quarters. The position peaked at $6K in Q3 2025. 4 funds tracked by Wall St. Rank hold VRAX as of Q1 2026.

  • National Bank of Canada reported no remaining Virax Biolabs position as of Q1 2026 after selling out during the quarter.
  • National Bank of Canada sold 240 Virax Biolabs shares in Q1 2026, an estimated $2.07K.
  • National Bank of Canada first reported a position in Virax Biolabs in Q2 2025 and held it in 3 quarters.
  • National Bank of Canada's Virax Biolabs position peaked at $6K in Q3 2025.
  • 4 funds tracked by Wall St. Rank held Virax Biolabs as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.